Intech Biopharm Statistics

Total Valuation

Intech Biopharm has a market cap or net worth of TWD 3.10 billion. The enterprise value is 4.28 billion.

Market Cap	3.10B
Enterprise Value	4.28B

Important Dates

The last earnings date was Thursday, March 13, 2025.

Earnings Date	Mar 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Intech Biopharm has 137.94 million shares outstanding. The number of shares has increased by 13.97% in one year.

Current Share Class	n/a
Shares Outstanding	137.94M
Shares Change (YoY)	+13.97%
Shares Change (QoQ)	+0.00%
Owned by Insiders (%)	1.27%
Owned by Institutions (%)	1.92%
Float	74.63M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	77.65
PB Ratio	3.81
P/TBV Ratio	3.83
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-11.63
EV / Sales	107.63
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-13.69

Financial Position

The company has a current ratio of 1.06, with a Debt / Equity ratio of 1.76.

Current Ratio	1.06
Quick Ratio	0.72
Debt / Equity	1.76
Debt / EBITDA	n/a
Debt / FCF	-4.59
Interest Coverage	-10.43

Financial Efficiency

Return on equity (ROE) is -37.15% and return on invested capital (ROIC) is -9.17%.

Return on Equity (ROE)	-37.15%
Return on Assets (ROA)	-8.72%
Return on Invested Capital (ROIC)	-9.17%
Return on Capital Employed (ROCE)	-17.73%
Revenue Per Employee	441,989
Profits Per Employee	-4.09M
Employee Count	90
Asset Turnover	0.02
Inventory Turnover	3.75

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -19.64% in the last 52 weeks. The beta is 0.34, so Intech Biopharm's price volatility has been lower than the market average.

Beta (5Y)	0.34
52-Week Price Change	-19.64%
50-Day Moving Average	24.84
200-Day Moving Average	27.54
Relative Strength Index (RSI)	33.66
Average Volume (20 Days)	86,395

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Intech Biopharm had revenue of TWD 39.78 million and -368.21 million in losses. Loss per share was -2.68.

Revenue	39.78M
Gross Profit	-157.63M
Operating Income	-356.13M
Pretax Income	-368.21M
Net Income	-368.21M
EBITDA	-269.80M
EBIT	-356.13M
Loss Per Share	-2.68

Full Income Statement

Balance Sheet

The company has 258.65 million in cash and 1.44 billion in debt, giving a net cash position of -1.18 billion or -8.54 per share.

Cash & Cash Equivalents	258.65M
Total Debt	1.44B
Net Cash	-1.18B
Net Cash Per Share	-8.54
Equity (Book Value)	814.28M
Book Value Per Share	5.90
Working Capital	23.68M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -269.22 million and capital expenditures -43.62 million, giving a free cash flow of -312.84 million.

Operating Cash Flow	-269.22M
Capital Expenditures	-43.62M
Free Cash Flow	-312.84M
FCF Per Share	-2.27

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-895.26%
Pretax Margin	-925.63%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Intech Biopharm does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-13.97%
Shareholder Yield	-13.97%
Earnings Yield	-11.86%
FCF Yield	-10.08%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Intech Biopharm has an Altman Z-Score of 0.68. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.68
Piotroski F-Score	n/a